Japanease

Feb. 27, 2020

June. 29, 2020

jRCTs031190226

A prospective multi-center open trial to evaluate the safety and efficacy of favipiravir in patients infected with COVID-19.

Favipiravir in patients infected with COVID-19

Tokue Yutaka

Gunma Universty Hospital

3-39-15 Showa-mchi, Maebashi-shi, Gunma

+81-27-220-8549

tokue49@gmail.com

Nakamura Tetsuya

Gunma Universty Hospital

3-39-15 Showa-mchi, Maebashi-shi, Gunma

+81-27-220-8740

nakamurt@gunma-u.ac.jp

Mar. 14, 2020

100

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

none

positive result for COVID-19 detection test
fever above 37.5 degree Celsius, or pneumonia shadow on chest X-ray or CT-scan
hospital admission

pregnancy
lactation

20age old over
No limit

Both

patients infected with COVID-19

oral administration of favipiravir

Coronavirus

expected value and 95% CI of ratio of C-reactive protein before versus after the treatment

disappearance rate of COVID-19

Recruiting

Gunma University Hospital Clinical Research Review Board
3-39-15 Showa-mchi, Maebashi-shi, Gunma

+81-27-220-8740

irb-jimukk-ciru@ml.gunma-u.ac.jp
Approval

Feb. 26, 2020